Everolimus improved progression-free survival by 6 to 8 months compared with placebo in patients with advanced neuroendocrine tumors of the gastrointestinal tract.
A novel drug, 177Lutetium-DOTATATE (Lutathera), significantly lowered the risk for disease progression or death among patients with previously treated, advanced midgut neuroendocrine tumors.
Small- and large-cell neuroendocrine tumors of the cervix are exceedingly rare and exceedingly aggressive.
Small intestinal “carcinoid” or well-differentiated grade 1 neuroendocrine tumors can have an insidious onset or be diagnosed serendipitously at the time of surgery, during the workup for another disorder, or during a screening test.
Nonfunctional neuroendocrine tumors of lung or gastrointestinal origin were safely and effectively treated with the mTOR inhibitor everolimus.
Patients with midgut neuroendocrine tumors had significantly delayed disease progression when treated with Lutathera compared with the current standard of care.
The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
In patients with advanced, unresectable NETs, there are several treatment options; which of these may be considered depends on the site of origin of the tumor.
Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.
Treatment-emergent small-cell/neuroendocrine prostate cancer is likely to become of increasing clinical relevance in the era of widespread use of potent androgen receptor–targeted therapies.